Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose.

Abstract

CONTEXT:

Hypophosphatemia, osteomalacia, and fractures are complications of certain intravenous iron formulations.

OBJECTIVE:

This study investigated risk factors for incident, severe, and persistent hypophosphatemia, and associated alterations in bone and mineral biomarkers following intravenous iron treatment.

METHODS:

We analyzed data from the PHOSPHARE-IDA randomized clinical trials, comprising 245 patients aged 18 years or older with iron deficiency anemia at 30 outpatient clinics in the United States who received intravenous ferric carboxymaltose (FCM) or ferric derisomaltose (FDI). Outcome measures included serum phosphate, intact fibroblast growth factor-23 (iFGF23), 1,25-dihydroxyvitamin D (1,25(OH)2D), ionized calcium, parathyroid hormone (PTH), and alkaline phosphatase.

RESULTS:

FCM was the only consistent risk factor for incident hypophosphatemia (< 2.0 mg/dL; odds ratio vs FDI: 38.37; 95% CI: 16.62, 88.56; P < 0.001). Only FCM-treated patients developed severe hypophosphatemia (< 1.0 mg/dL; 11.3%; 13/115) or persistent hypophosphatemia (< 2.0 mg/dL at study end; 40.0%; 46/115). More severe hypophosphatemia associated with significantly greater increases in iFGF23, PTH, and alkaline phosphatase, and more severe decreases in 1,25(OH)2D and ionized calcium (all P < 0.05). Patients with persistent vs resolved hypophosphatemia demonstrated significantly greater changes in iFGF23, PTH, 1,25(OH)2D, and N-terminal procollagen-1 peptide levels (all P < 0.01), but alkaline phosphatase increased similarly in both groups.

CONCLUSION:

Treatment with FCM was the only consistent risk factor for hypophosphatemia. Patients who developed severe or persistent hypophosphatemia after FCM treatment manifested more severe derangements in bone and mineral metabolism. Changes in bone biomarkers continued beyond resolution of hypophosphatemia, suggesting ongoing effects on bone that may help explain the association of FCM with osteomalacia and fractures.

• Authors: Benedikt Schaefer, Heinz Zoller, Myles Wolf
• Journal: The Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 107 Issue 4 Pg. 1009-1019 (03 24 2022) ISSN: 1945-7197 [Electronic] United States
• PMID: 34850000 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.

Chemical References

• Biomarkers
• Disaccharides
• Ferric Compounds
• Minerals
• Parathyroid Hormone
• ferric carboxymaltose
• Maltose
• ferric derisomaltose
• Iron
• Alkaline Phosphatase
• Calcium

Topics

• Alkaline Phosphatase (therapeutic use)
• Anemia, Iron-Deficiency (complications, drug therapy)
• Biomarkers
• Calcium (therapeutic use)
• Disaccharides
• Familial Hypophosphatemic Rickets (complications)
• Female
• Ferric Compounds
• Humans
• Hypophosphatemia (chemically induced, epidemiology)
• Iron
• Male
• Maltose (analogs & derivatives)
• Minerals
• Osteomalacia
• Parathyroid Hormone (therapeutic use)
• Risk Factors